Management of Peripheral Artery Disease Patients on Anticoagulation

Antiplatelet Therapy Recommendations

The American College of Cardiology recommends that, for patients with peripheral artery disease (or stable ischemic heart disease) who are medically managed and have therapeutic anticoagulation initiated, aspirin should be discontinued. 1
This recommendation is reiterated in the 2021 ACC guideline, stating that antiplatelet therapy should be stopped when therapeutic anticoagulation is established in this population. 2
The guideline explicitly classifies the cessation of aspirin in medically managed PAD patients on anticoagulation as a Class I recommendation. 3

For patients who have both atrial fibrillation and a recent venous thromboembolism, the ACC guideline advises using the VTE‑treatment dose of apixaban (5 mg twice daily) rather than the lower dose used for stroke prophylaxis alone (2.5 mg twice daily). 1
The same guideline emphasizes that the higher VTE‑specific dose provides adequate anticoagulation for both indications. 2
After six months of treatment, the guideline allows consideration of stepping down to the lower maintenance dose of apixaban (2.5 mg twice daily) for indefinite secondary prevention, provided the patient remains stable. 3

In patients who are less than 6 months post‑percutaneous coronary intervention (PCI), the ACC recommends stopping aspirin and continuing clopidogrel together with apixaban. 3
Between 6 and 12 months after PCI, either aspirin or clopidogrel (but not both) may be continued alongside apixaban. 3
More than 12 months after PCI, apixaban alone is recommended. 3
For patients less than 1 year after coronary artery bypass grafting (CABG), low‑dose aspirin (<100 mg daily) may be continued together with apixaban. 3

Continuing aspirin “just in case” for cardiovascular protection in patients already on therapeutic anticoagulation is discouraged, as it raises bleeding risk without proven benefit. 3
Adding aspirin to apixaban in medically managed PAD patients does not improve outcomes and significantly increases major bleeding risk; therefore, it should be avoided. 3
Concomitant use of non‑steroidal anti‑inflammatory drugs (NSAIDs) with apixaban should be avoided because of additive bleeding risk. (Guideline‑based precaution) 3

The American College of Cardiology recommends that for most patients on apixaban, aspirin 81mg should be stopped, as the combination significantly increases bleeding risk without providing additional thromboembolic protection 4, 5, 6

For patients with atrial fibrillation alone, the American College of Cardiology recommends stopping aspirin immediately when starting apixaban, as apixaban monotherapy provides superior stroke prevention compared to aspirin with lower bleeding risk 5, 7
For patients with stable coronary disease, the American College of Cardiology recommends stopping aspirin for medically managed stable ischemic heart disease or peripheral artery disease once apixaban is established 4, 5, 6
For patients with recent percutaneous coronary intervention (PCI), the American College of Cardiology recommends a time-based algorithm: stop aspirin and continue P2Y12 inhibitor (clopidogrel preferred) + apixaban for <6 months post-PCI, continue either aspirin or clopidogrel (not both) + apixaban for 6-12 months post-PCI, and stop all antiplatelet therapy and continue apixaban alone for >12 months post-PCI 4, 5, 6, 7

The American College of Cardiology recommends no aspirin when apixaban is used for VTE treatment or prevention, as apixaban monotherapy provides complete anticoagulation 4, 6

The American College of Cardiology notes that adding aspirin to apixaban increases major bleeding risk, and recommends avoiding combination therapy in patients with NSAID use, active cancer, or history of gastrointestinal bleeding 4, 6
The American College of Cardiology recommends verifying the apixaban indication and dose, as VTE requires higher dosing than atrial fibrillation, and aspirin is never indicated for VTE 4, 6